![Naji Gehchan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Naji Gehchan
Directeur Technique/Scientifique/R&D chez
KYVERNA THERAPEUTICS, INC.
Fortune : - $ au 31/05/2026
Profil
Naji H.
Gehchan, M.D.
has served as our Chief Medical and Development Officer since January 2025.
Dr. Gehchan is an accomplished biopharmaceutical physician-executive with extensive experience in drug development, commercialization and general management.
Most recently, Dr. Gehchan served as Head of Clinical Development Oncology for imlunestrant at Eli Lilly & Co. (NYSE: LLY), from April 2021 to January 2025.
In this role, he built and led high-performing teams to advance with agility and speed Eli Lilly’s next-generation oral SERD from Phase 1 to global submission.
Dr. Gehchan joined Eli Lilly in October 2008, holding various leadership roles across geographies and functions.
From September 2019 to April 2021, he served as Associate Vice President of Sales on the U.S.
Diabetes Leadership Team.
Previously, he served as Chief Marketing Officer and Business Unit Head, BioMedicines, from August 2015 to September 2019, leading the launches of Eli Lilly’s immunology portfolio across France and other European countries.
Prior to joining Eli Lilly, he worked at Johnson & Johnson as a Medical Advisor, Internal Medicine & Health Economics from April 2008 to October 2008.
Dr. Gehchan also served as an Attending Physician and Resident in internal medicine at Hotel-Dieu de France and CHU Montpellier from June 2005 to June 2007.
In addition to his professional career, Dr. Gehchan has been a Faculty Mentor and Guest Lecturer at MIT Sloan since 2023, and a Lecturer in Leadership and Management at ESCP Business School since 2019.
Dr. Gehchan earned his Doctor of Medicine in 2006, and Masters in Biological Sciences (Genetics and Immunology) in 2004 from Saint Joseph University of Beirut, a Specialized Masters in Healthcare Management from ESCP Business School in 2009, and an Executive Master of Business Administration from the Massachusetts Institute of Technology Sloan in 2022.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/03/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Naji Gehchan
| Sociétés | Poste | Début |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 22/01/2025 |
Anciens postes connus de Naji Gehchan
| Sociétés | Poste | Fin |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Formation de Naji Gehchan
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
4
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
MIT Sloan School of Management
 MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kyverna Therapeutics, Inc.
 Kyverna Therapeutics, Inc. BiotechnologyHealth Technology Operates as a cell therapy company which develops treatments and potential cures for serious autoimmune diseases | Health Technology |
Saint Joseph University of Beirut
 Saint Joseph University of Beirut Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
